Abstract
Adding the PD-L1 inhibitor durvalumab to chemotherapy before and after surgery led to improved pathological complete response rates and event-free survival in patients with untreated, operable non-small cell lung cancer, according to interim results from the AEGEAN trial. Researchers noted that administering immunotherapy prior to surgery may help in developing more tailored adjuvant treatments based on patients' responses and tumor characteristics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
